Patents Assigned to Kinki University
  • Patent number: 12102713
    Abstract: Provided are an ocular surface drug-retaining agent that enables an excellent improvement in retainability of a medicament on an ocular surface and an eye drop containing the agent. An ocular surface drug-retaining agent containing a copolymer having three different kinds of constituent units at a specific ratio can express an excellent effect of retaining a medicament on an ocular surface (in particular, a corneal surface) to allow the effect or action of the drug to be sustained over a long period of time.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: October 1, 2024
    Assignees: NOF CORPORATION, Kinki University
    Inventors: Noriaki Nagai, Shunsuke Sakurai, Eiji Harata
  • Publication number: 20240084037
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 14, 2024
    Applicants: Daiichi Sankyo Co., Ltd., Daiichi Sankyo Europe GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Patent number: 11873344
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: January 16, 2024
    Assignees: Daiichi Sankyo Co., Ltd., Daiichi Sankyo Europe GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin, Kimio Yonesaka, Kazuhiko Nakagawa
  • Patent number: 11420944
    Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: August 23, 2022
    Assignees: Nippon Chemiphar Co., Ltd., Kinki University
    Inventors: Hiroto Tanaka, Isao Ooi, Yuzo Mogi, Masaaki Hirose, Tsuyoshi Endo, Toru Ogawa, Atsufumi Kawabata
  • Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • Patent number: 11370761
    Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydr
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 28, 2022
    Assignees: Nippon Chemiphar Co., Ltd., Kinki University
    Inventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata
  • Publication number: 20210003579
    Abstract: Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).
    Type: Application
    Filed: September 23, 2020
    Publication date: January 7, 2021
    Applicants: KYOTO UNIVERSITY, Kinki University, ONO PHARMACEUTICAL CO., LTD., SYSMEX CORPORATION
    Inventors: Tasuku HONJO, Kenji CHAMOTO, Hidetoshi HAYASHI, Kazuhiko NAKAGAWA, Megumi GOTO, Hitoshi UGA
  • Publication number: 20200115467
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: August 21, 2019
    Publication date: April 16, 2020
    Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Patent number: 10562775
    Abstract: The present invention provides a method for producing a carbon nanotube sheet that is excellent in light transmittance and conductivity, and the carbon nanotube sheet. The method includes firstly modifying of modifying a free-standing unmodified carbon nanotube sheet in which a plurality of carbon nanotubes are aligned in a predetermined direction. The firstly modifying includes performing a densification process of bringing the unmodified carbon nanotube sheet into contact with either one of or both of vapor and liquid particles of a liquid substance to produce a modified carbon nanotube sheet that contains the carbon nanotubes which are mainly aligned in a predetermined direction, and that includes a high density portion where the carbon nanotubes are assembled together and a low density portion where density of the carbon nanotubes is relatively lower than density in the high density portion.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: February 18, 2020
    Assignees: Lintec Corporation, Lintec of America, Inc., Kinki University
    Inventors: Raquel Ovalle, Senku Tanaka, Kanzan Inoue
  • Patent number: 10487306
    Abstract: Provided are a novel cultivation method and a storage method that are suitable for storing bacteria belonging to the genus Collimonas for a long period of time. The cultivation method for bacteria belonging to the genus Collimonas is characterized in that bacteria belonging to the genus Collimonas are cultivated in a sealed state on a culture medium that includes a rice bran culture medium and/or a soy pulp culture medium. The storage method for bacteria belonging to the genus Collimonas is characterized in that the cultivated bacteria belonging to the genus Collimonas are stored at room temperature.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: November 26, 2019
    Assignees: New Environmental Technology Council, Kinki University
    Inventors: Takashi Ano, Toichiro Hirose
  • Patent number: 10449070
    Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 22, 2019
    Assignees: Kinki University, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshimasa Ito
  • Publication number: 20190077767
    Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each repres
    Type: Application
    Filed: January 12, 2017
    Publication date: March 14, 2019
    Applicants: Nippon Chemiphar Co., Ltd., Kinki University
    Inventors: Hiroto TANAKA, Isao OOI, Yuzo MOGI, Masaaki HIROSE, Tsuyoshi ENDO, Toru OGAWA, Atsufumi KAWABATA
  • Patent number: 10155804
    Abstract: To provide a differentiation-inducing composition and a method for producing the differentiation-inducing composition, the present disclosure describes use of a degradation product containing at least a portion of the triple helical domain of collagen or atelocollagen.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: December 18, 2018
    Assignee: Kinki University
    Inventors: Koichi Morimoto, Saori Kunii, Ei Yamamoto, Hiroyuki Ito, Yoshinori Kuboki
  • Publication number: 20180027748
    Abstract: The purpose of the present invention is: to produce a metabolite capable of improving drought tolerance of a plant to the same level as that achieved by abscisic acid, from a microorganism other than a microorganism that is known to be capable of producing abscisic acid; and to provide a method for improving drought tolerance of a plant using the metabolite. A method for producing a metabolite capable of improving drought tolerance using a microorganism, said method comprising culturing a microorganism that belongs to the genus Collimonas and has an ability of producing a metabolite capable of improving drought tolerance of a plant and then extracting the metabolite from a culture produced by the culturing.
    Type: Application
    Filed: February 10, 2015
    Publication date: February 1, 2018
    Applicants: New Environmental Technology Council, Kinki University
    Inventors: Takashi ANO, Yoichiro HIROSE
  • Patent number: 9725519
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains an antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 8, 2017
    Assignees: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • Publication number: 20170166654
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20160345587
    Abstract: A method for producing a cell extract having agricultural pest insecticidal capacity by culturing filamentous fungi having insecticidal capacity for an agricultural pest, and a method for insecticide produced by this production method. A method for producing a cell extract having agricultural pest insecticidal capacity provided with a step for culturing filamentous fungi in solid medium and obtaining a solid culture of the filamentous fungi, a step for culturing the filamentous fungi in liquid medium and obtaining a liquid culture of the filamentous fungi, a step for separating mycelia of the filamentous fungi from the liquid culture of the filamentous fungi, a step for mixing the liquid culture from which the mycelia have been removed and the solid culture and obtaining a mixed culture, and a step for extracting a spore solution of the filamentous fungi from this mixed culture.
    Type: Application
    Filed: February 10, 2014
    Publication date: December 1, 2016
    Applicants: Towada Green Tuff Agro-science Co., Ltd., Kinki University
    Inventors: Takashi ANO, Yoichiro HIROSE
  • Patent number: 9057067
    Abstract: A method for transfecting nucleic acid to cell comprising a step for forming a nucleic acid complex by bringing a double-stranded nucleic acid molecule into contact with a nucleic acid carrier having an amino acid sequence of alternating a basic amino acid and a hydrophobic amino acid, which has a peptide chain that forms a ?-sheet structure in which a side chain of a positively charged basic amino acid is disposed on one surface side and a side chain of a hydrophobic amino acid is disposed on the opposite surface side in the presence of the double-stranded nucleic acid molecule having a double helix structure, and by binding the double-stranded nucleic acid molecule and the peptide chain through either one or both of the electrostatic interaction between the side chains of the basic amino acid and phosphate groups and hydrogen bonds between the double stranded-nucleic acid molecule and the peptide chain and a nucleic acid complex used for the same are disclosed.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: June 16, 2015
    Assignee: Kinki University
    Inventor: Masayuki Fujii
  • Publication number: 20150147278
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 28, 2015
    Applicants: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA